Hepatocellular carcinoma (HCC) represents the fifth most common cancer worldwide with its incidence also continuously increasing in Europe or North America \[[@B1]\]. In the majority of cases, HCC arises in cirrhotic livers. Despite the recommendation of regular ultrasound surveillance in cirrhotic patients, potentially leading to earlier diagnoses, many patients present with an intermediate or advanced stage of the disease, according to the Barcelona Clinic of Liver Cancer (BCLC) staging system, at the time of diagnosis \[[@B2]\]. The BCLC classification subdivides patients with respect to their tumor burden, the degree of liver dysfunction and performance status into five different classes (BCLC 0 and A--D). Patients with advanced disease stages, as well as patients in intermediate stages which has progressed under locoablative therapies, should receive systemic treatments as long as liver function and performance status are well preserved.

Until recently, patients with a need for systemic treatment were left to toxic and only moderately effective therapies with tyrosine kinase inhibitors (TKIs) leading to often dismal prognoses \[[@B3]\]. After many negative trials, novel treatments are urgently needed \[[@B4]\]. In this context, immunotherapies have been introduced into therapeutic algorithms of many cancers including malignant melanoma, lung cancer or hematological malignancies \[[@B5]\]. In patients with hepatocellular cancer, such therapies seemed particularly promising, since almost all HCC develop in cirrhotic livers that bear an immunosuppressive environment that might be modulated by, for example, checkpoint inhibitors \[[@B6]\]. In line, early Phase I/II trials raised hope for a swift introduction into therapeutic algorithms for patients with HCC \[[@B7],[@B8]\]. Moreover, ramucirumab, a novel antibody directed against VEGFR2 has demonstrated efficacy when used in patients with elevated serum AFP levels \[[@B9]\]. Thus, in contrast to the period before 2016, plenty of different compounds are now available for use in HCC ([Table 1](#T1){ref-type="table"}). However, as the efficacy of single agents used sequentially still appears limited, combination therapies including different substance classes have been tested, which will potentially change treatment algorithms in the near future ([Table 2](#T2){ref-type="table"}). In this review, we summarize results from recent clinical trials analyzing these novel substances in the context of HCC. Furthermore, we discuss current indications and outline a novel treatment algorithm for use in HCC patients in need for systemic therapy.

###### Selected Phase III studies in the context of the hepatocellular carcinoma.

  Study name      NCT           Line of treatment    Experimental arm             Control arm   Primary end point     Overall survival (months)                Hazard ratio
  --------------- ------------- -------------------- ---------------------------- ------------- --------------------- ---------------------------------------- ---------------------
  SHARP           NCT00105443   1\. line             Sorafenib                    Placebo       OS                    10.7 vs 7.9                              0.69
  REFLECT         NCT01761266   1\. line             Lenvatinib                   Sorafenib     OS (noninferiority)   13.6 vs 12.3                             0.92
  Imbrave 150     NCT03434379   1\. line             Bevacizumab + atezolizumab   Sorafenib     OS/PFS                N/A[^†^](#T1TFN1){ref-type="table-fn"}   0.58
  CheckMate 459   NCT02576509   1\. line             Nivolumab                    Sorafenib     OS                    16.4 vs 14.7                             0.85 (p = 0.07)
  RESORCE         NCT01774344   2\. line             Regorafenib                  Placebo       OS                    10.7 vs 7.8                              0.63
  CELESTIAL       NCT01908426   2\. line and later   Cabozantinib                 Placebo       OS                    10.2 vs 8.0                              0.76
  REACH-2         NCT02435433   2\. line             Ramucirumab                  Placebo       OS                    8.5 vs 7.3                               0.71
  Keynote-240     NCT02702401   2\. line             Pembrolizumab                Placebo       OS                    13.9 vs 10.6                             0.78 p = 0.02; n.s.

Values not available at time of manuscript creation.

n.s.: Not significant; OS: Overall survival; PFS: Progression-free survival.

###### Ongoing clinical trials of combination therapies in hepatocellular carcinoma.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial name/identifier                                          Setting                                                                      Treatment                                                  Primary end points
  -------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------------------------------
  **Phase I/II trials**                                                                                                                                                                                   

  GO30140/NCT02715531[^†^](#T2TFN1){ref-type="table-fn"}         Advanced HCC/first-line                                                      Bevacizumab + atezolizumab                                 Safety, ORR, PFS

  NCT03006926                                                    Advanced HCC/first-line                                                      Lenvatinib + pembrolizumab                                 Dose escalation: safety, DLTs\
                                                                                                                                                                                                         Dose expansion: ORR, DOR

  NCT03418922                                                    Advanced HCC/first-line                                                      Lenvatinib+ nivolumab                                      Part 1: DLTs, safety\
                                                                                                                                                                                                         Part 2: safety

  NCT03895970                                                    Advanced hepatobiliary tumors/second-line                                    Lenvatinib + pembrolizumab                                 ORR, DCR, PFS

  CheckMate 040/NCT01658878[^†^](#T2TFN1){ref-type="table-fn"}   Advanced HCC/first- or second-line                                           Cabozantinib + nivolumab ± ipilimumab                      Safety, ORR

  COSMIC-021/NCT03170960                                         Advanced solid tumors, HCC/first-line                                        Cabozantizib + atezolizumab                                Dose escalation: MTD, recommended dose\
                                                                                                                                                                                                         Dose expansion: ORR

  CaboNivo/NCT03299946                                           Locally advanced HCC/neoadjuvant                                             Cabozantizib + nivolumab                                   Safety, number of patients who complete preoperative treatment and proceed to surgery

  CAMILLA/NCT03539822                                            Advanced GI tumors, HCC/second-line                                          Cabozantizib + durvalumab                                  MTD

  NCT03347292                                                    Advanced HCC/first-line                                                      Regorafenib + pembrolizumab                                Safety, DLTs

  REGOMUNE/NCT03475953                                           Advanced GI tumors, HCC/second-line                                          Regorafenib + avelumab                                     Part 1: recommended Phase II dose of regorafenib\
                                                                                                                                                                                                         Part 2: ORR

  NCT02572687                                                    Advanced solid tumors, HCC/second-line and AFP ≥1.5× upper limit of normal   Ramucirumab + durvalumab                                   DLTs

  NCT02082210                                                    Advanced solid tumors, HCC/second-line                                       Ramucirumab + emibetuzumab                                 Part A: DLTs\
                                                                                                                                                                                                         Part B: ORR

  NCT02423343                                                    Advanced solid tumors, HCC/second-line and AFP ≥200 ng/ml                    Galunisertib + nivolumab                                   Phase Ib: MTD

  **Phase III trials**                                                                                                                                                                                    

  LEAP-002/NCT03713593                                           Advanced HCC/first-line                                                      Lenvatinib + pembrolizumab vs lenvatinib + placebo         PFS, OS

  COSMIC-312/NCT03755791                                         Advanced HCC/first-line                                                      Cabozantinib + atezolizumab vs sorafenib vs cabozantinib   PFS, OS
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Trials include other cohorts.

DCR: Disease control rate; DLT: Dose-limiting toxicity; DOR: Duration of response; GI: Gastrointestinal; HCC: Hepatocellular carcinoma; MTD: Maximum tolerated dose; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival.

Modified with permission from \[[@B10]\].

First-line systemic therapy {#S0001}
===========================

Tyrosine kinase inhibitors {#S0002}
--------------------------

Systemic therapies are recommended for patients in advanced disease stages (BCLC stage C) or for patients in intermediate-stage disease stages (BCLC stage B) that are not (or no longer) eligible for locoregional therapies \[[@B3]\]. In 2008, the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial established sorafenib as the standard for systemic treatment of HCC \[[@B11]\]. Sorafenib is a TKI, targeting mainly VEGFR2, PDGFR and KIT \[[@B12]\]. The SHARP study analyzed the efficacy and safety of sorafenib compared with placebo for first-line therapy of HCC patients with well-preserved liver function (Child-Pugh A), that were not eligible for surgical or locoregional therapies. Sorafenib was associated with a significantly increased median survival of 10.7 months compared with 7.9 months in patients receiving placebo (hazard ratio \[HR\]: 0.69; p \< 0.001). In line, progression-free survival (PFS) was significantly longer with sorafenib (5.5 vs 2.8 months; p \< 0.001), response rates were unaffected by the treatment (2% with sorafenib; 1% with placebo \[[@B11]\]). Similar efficacy was reported from Asia-Pacific trial (overall survival \[OS\]: 6.5 vs 4.2 months; HR: 0.68; p = 0.014 \[[@B13]\]). Both studies demonstrated an unfavorable toxicity profile with diarrhea, hand-foot syndrome, fatigue and anorexia representing the most common side effects. In a recently published meta-analysis sorafenib was demonstrated to be particularly efficient in those patients without extrahepatic spread, with hepatitis C virus infection and low neutrophil-to-lymphocyte ratio \[[@B14]\].

Since the introduction of sorafenib many other compounds including erlotinib \[[@B15]\], brivanib \[[@B16],[@B17]\], sunitinib \[[@B18]\], linifanib \[[@B19]\] and everolimus \[[@B20]\] have been tested in first-line treatment of HCC, without showing superiority (or at least noninferiority) to sorafenib (summarized in \[[@B21]\]). Therefore, sorafenib remained the sole first-line option until lenvatinib, another TKI, was shown as noninferior in 2018 \[[@B22]\].

Similar to sorafenib, lenvatinib represents an orally available TKI, targeting VEGFR1--3, FGFR1--4, PDGFR, RET and KIT \[[@B23]\]. In the context of HCC, lenvatinib was tested within the REFLECT-trial, representing an open-label, multicenter, noninferiority trial comparing sorafenib with lenvatinib in previously untreated patients with histologically proven advanced (or intermediate but not eligible for transarterial chemoembolization \[TACE\]) HCC. Although the study showed only a slight (and not significant) improvement in median survival in the lenvatinib arm (13.6 vs 12.3 months), there was a significant improvement in tumor response (objective response rate \[ORR\]: 24.1 vs 9.2%; p = 0.001) and time to progression (8.9 vs 3.7 months; p \< 0.0001). Response rates were significantly higher in patients receiving lenvatinib (18.8 vs 6.5%; p \< 0.001 according to Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1), arguing for a use of lenvatinib when tumor shrinkage is warranted. Further subgroup analyses showed that Asian patients, patients with hepatitis B virus infection and patients with high AFP serum concentrations (\>200 ng/ml) demonstrated a particular benefit from treatment with lenvatinib. Lenvatinib was associated with more frequent side effects than sorafenib, which might be due to longer treatment duration in the lenvatinib arm. Important high-grade adverse events were hypertension and weight loss for lenvatinib, as well as skin toxicity and diarrhea for sorafenib, respectively. Based on these data, current guidelines recommend both sorafenib and lenvatib for frontline treatment of unresectable HCC that are not amendable to surgery or transarterial therapies in case of BCLC B \[[@B24]\].

Immunotherapy {#S0003}
-------------

Tumor-associated antigens bound to major histocompatibility complex molecules are located on the surface of immune-presenting cells. Within lymph nodes, these cells present such antigens to immature T cells, which become activated and develop into so-called CD8-positive activated T cells that are able to recognize antigens located on tumor cells and upon activation, induce tumor cell death. This process is negatively regulated by so-called checkpoints such as PD-1 protein and CTLA4. PD-1 is a receptor, expressed on activated T and B cells as well as on myeloid cells. Activation of PD-1 by its ligands PD-L1 and PD-L2 inhibits T-cell activity, thereby causing immunosuppression. While PD-L1 is expressed in most tissues, PD-L2 is only expressed by antigen-presenting cells, highlighting the much more prominent function of PD-L1 in cancer immunity. Considering the immunosuppressive activity of the PD-1/PD-L1 complex, preventing the activation of the PD-1 receptor might help to restore the ability of immune cells to recognize and kill tumor cells. In contrast to PD-1/PD-L1, CTLA4, another immune checkpoint protein, which is mainly expressed on T cells, is most abundant in lymph nodes and specifically regulates the proliferation of activated lymphocytes. While in a physiological setting, CTLA4 is mainly responsible for terminating T-cell activity and for preventing an excess in T-cell responses, under malignant conditions, it inhibits the activation, proliferation and production of tumor antigen-activated T cells in the tumor microenvironment. Like anti-PD-1/PD-L1-directed antibodies, anti-CTLA-directed treatments may redirect the immune system to attack the tumor. Antibodies against both PD-1/PD-L1 and CTLA4 have proven efficacy in manifold tumor entities \[[@B25]\]. Most HCC arise in an immunosuppressive microenvironment that might be 're-activated' by immunomodulatory treatments \[[@B6]\]. Various immunotherapies have been tested in the context of HCC. Vaccinations including peptide vaccines against glypican-3 and oncolytic and dendritic cell vaccines were analyzed in early phase clinical trials and have demonstrated promising results (summarized in \[[@B26]\]). Moreover, JX-594 (an oncolytic pox virus vaccine) demonstrated activity in a Phase I study including ten patients with advanced HCC \[[@B27]\]. Based on these data, the Phase III PHOCUS trial (NCT02562755) was initiated, but was stopped after a first interim analysis according to a recent press release \[[@B28]\]. Results from these and other (e.g., HEPAVAC-101, NCT03203005, NCT03071094 and MASTERKEY-318) studies will further clarify the role of vaccine immunotherapy in HCC (summarized, e.g., in \[[@B29]\]).

Checkpoint inhibitors were recently introduced as a new class of substances for therapy of solid tumors \[[@B30]\]. The principle of these inhibitors is to overcome immune tolerance against the tumor, which is mediated by certain inhibitory molecules such as PD-1, the PD-1 ligand, PDL-1 or CTLA-4. In the context of HCC, the CheckMate-040 study, a nonrandomized Phase I/II study, which included 56 patients with therapy-naive patients, suggested that the checkpoint inhibitor nivolumab might be effective for first-line therapy of patients with advanced HCC (ORR of 13% and 6- and 9-month survival rates of 89 and 82%, respectively \[[@B7]\]). Just recently, the results of the much larger, randomized CheckMate-459 study investigating the efficacy of nivolumab in Phase III design were presented \[[@B31]\]. In this study, a total of 743 patients were randomized into an experimental arm receiving nivolumab (240 mg intravenously every 2 weeks \[Q2W\]) and a control arm receiving sorafenib. However, no difference in OS and PFS was demonstrated in either the IIT or PD-L1-positive cohort (OS IIT cohort 16.4 vs 14.7 months; p = 0.0752 and PFS IIT cohort 3.7 vs 3.8 months). Although tumor response was slightly better for nivolumab (ORR: 15 vs 7%), disease control rates were comparable between both arms (55 vs 58%). As expected, the toxicity profile of nivolumab was significantly better than that of sorafenib. Although many experts considered results of CheckMate-459 as 'clinically meaningful', the study remains statistically negative and nivolumab should not be used in routine care of patients with untreated, advanced HCC.

Besides nivolumab, the combination of bevacizumab (VEGF-antibody) and atezolizumab (PD-L1 antibody) was recently tested for first-line treatment of patients with HCC. First, the multi-arm Phase Ib GO301240 study had provided evidence for the efficacy of this combination by randomizing 119 patients with advanced HCC to receive either the combination of bevacizumab/atezolizumab or a atezolizumab as a single agent \[[@B31]\]. In this analysis, the doublet was associated with excellent tumor response (12% complete remission, 24% partial remission and 35% stable disease according to RECIST 1.1) and superior to single therapy in terms of PFS (5.6 vs 3.4 months; HR: 0.55). These results were confirmed by data from the Phase III, multicenter IMBRAVE-150 study \[[@B32]\]. In this study, a total of 501 patients with advanced HCC were randomized between the combination of atezolizumab plus bevacizumab in the experimental arm and sorafenib in the control arm. OS and PFS were tested in parallel as primary end points. The combination was associated with a significantly improved survival: in the combination arm 6-month survival rate was 85%, compared with 72% in the sorafenib arm. Median survival was not yet achieved in the combination arm; in the sorafenib arm, it was 13.2 months (HR: 0.55). Similarly, PFS was significantly longer in patients receiving immunotherapy than in those receiving TKI (6.8 vs 4.3 months; HR: 0.59). Further subgroup analyses confirmed the superiority of the combination therapy in all subgroups. However, a somewhat weaker effect was observed in patients with nonviral hepatitis (HR: 0.91). Similar to GO301240 (and to CheckMate 459), administration of immunotherapy resulted in a remarkable response rates (27 vs 12%; p \< 0.0001). With regard to toxicity, IMBRAVE-150 did not reveal any new aspects: immunotherapy was less toxic than TKI therapy, which also translated into a better quality of life for the patients treated with atezolizumab plus bevacizumab. The authors of the study concluded that atezolizumab plus bevacizumab should be considered as a practice-changing treatment for patients with unresectable HCC, who have not received prior systemic therapy.

Further studies are currently underway to test the efficacy and safety of other combinations ([Table 2](#T2){ref-type="table"}). Promising data are available for the combination of lenvatinib and pembrolizumab, which is tested within an open-label, Phase Ib study including 104 HCC-patients with BCLC stage B (not amenable for TACE) or BCLC C, Child-Pugh class A. At present, data from the first 67 patients enrolled by 31 December 2018 are available \[[@B33]\]. Serious adverse events occurred in 62.7% of all patients, ORR was 44.8%. Results thus compared favorably with the lenvatinib arm of REFLECT trial (ORR: 24.1%). Median duration of response was 18.7 months, highlighting the tremendous potential of this combination. A Phase III trial (LEAP-002; NCT03713593) is ongoing. Moreover, just recently, results from the cabozantinib cohort of the CheckMate-040 study were presented. Within this cohort, patients with advanced HCC (\~50% therapy naive) were randomized between a doublet arm receiving nivolumab/cabozantinib and a triplet arm receiving nivolumab/ipilimumab/cabozantinib. In both arms, high response rates (19 and 29%, respectively) were observed, which translated in numerically high PFS (5.4 vs 6.8 months) and OS (21.5 months vs not reached) in both arms. Toxicity was comparable to other combination therapies (47 vs 71% grade 3/4 events \[[@B34]\]).

In summary, IMBRAVE-150 will likely change the way HCC is treated in the near future. Other combinations are currently being tested and it remains to be seen how available results from smaller studies will translate into large Phase III trials, and how this will compare with the current data from IMBRAVE-150. Further progress in immunotherapy for HCC will critically rely on the identification of predictive biomarkers that allow early identification of 'responders' \[[@B35]\]. It should be critically noted, that previous studies on immunotherapy have exclusively been conducted in patients with good liver function (Child-Pugh A). Currently, it is unclear to what extent this effect can be transferred to patients with impaired liver function.

### Cytotoxic chemotherapy {#S0004}

HCC does not respond to classical chemotherapy. Nevertheless, recently, the EACH study \[[@B36]\] demonstrated increased PFS/ORR and a trend toward an improved survival in Asian HCC patients treated with FOLFOX4 compared with patients that received placebo. It was recently demonstrated that oxaliplatin induces immunogenic cell death and activates an antitumor immune response \[[@B37]\]. In line, a potential synergistic role of oxaliplatin with immune checkpoint blockades was suggested in an animal model for colorectal cancer \[[@B38]\]. Based on the these data, a Phase II trial of SHR-1210 plus FOLFOX4 was recently initiated in Chinese patients with advanced HCC (NCT03092895, summarized in \[[@B39]\]).

### Transarterial chemoembolization {#S0005}

TACE is the standard palliative therapy for patients with HCC in stage BCLC B. Additional systemic chemotherapy could improve the efficacy of TACE. However, previous studies analyzing combinations of TACE and systemic therapy have all yielded negative results \[[@B40],[@B41]\]. Recently, the TACTICS study, a prospective multicenter randomized trial to evaluate the effect of a combination of TACE + sorafenib compared with TACE alone revealed surprisingly promising results \[[@B42]\]. Within this study, patients were treated with 400 mg sorafenib per day for 2--3 weeks before the first TACE, followed by 800 mg sorafenib once daily and TACE 'on demand'. Of note, the study used an innovative end point, time to untreatable (unTACEable) progression, defined as tumor progression into 'no longer treatable by TACE', transient deterioration of liver function to Child-Pugh class C or occurrence of macrovascular invasion or extrahepatic infestation. Interestingly, a significant improvement of this end point was shown by the addition of sorafenib. Data for OS are not yet available. Combinations of immunotherapy and TACE are currently being evaluated (summarized in \[[@B29],[@B43]\]).

Selective internal radiation therapy {#S0006}
------------------------------------

Radioembolization techniques apply radioactive substances (most often Yttrium-90 containing microspheres) via the hepatic artery. Data from the European SARAH study and the Asian SIRVeniB study, which compared the toxicity and efficacy of selective internal radiation therapy (SIRT) with that of sorafenib failed to demonstrate superiority of SIRT over sorafenib in patients with nonsystemically pretreated HCC. However, the SIRT arm performed significantly better in terms of toxicity and quality of life \[[@B44],[@B45]\]. In this context, the SORAMIC study analyzed efficacy and safety of the combination of SIRT plus sorafenib in patients with advanced HCC in a prospective randomized Phase II design \[[@B46]\]. The intent-to-treat cohort included 216 patients in the SIRT plus sorafenib arm and 208 patients in the sorafenib arm. Median OS was comparable in both arms (12.1 vs 11.4 months; HR: 1.01). Analysis of the per protocol cohort showed similar results. In further subgroup analyses, patients under 65 years of age (HR: 0.65; p = 0.05), patients without liver cirrhosis (HR: 0.46; p = 0.02) and patients with nonalcoholic etiology (HR: 0.63; p = 0.012) seemed to benefit particularly from the combination. The combination therapy was associated with slightly increased toxicity (grade ≥3 side effects in 64.8% of patients in the combination arm vs 53.8% in the patients receiving sorafenib). Overall, none of the available studies support the use of SIRT in (unselected) patients with advanced HCC eligible for systemic therapy.

### Second/later-line therapy {#S0007}

#### Tyrosine kinase inhibitors {#S0008}

In the SHARP/ASIAN and REFLECT studies, it was shown that administration of TKIs only leads to relatively short periods of tumor control. Based on data from the RESORCE- and CELESTIAL-studies, both regorafenib and cabozantinib are approved for use in patient's refractory to sorafenib \[[@B47],[@B48]\]. RESORCE compared the efficacy of regorafenib in patients after failure of a sorafenib-based first-line therapy against placebo \[[@B47]\]. The primary end point was OS; secondary end points were PFS, ORR and safety profile. The study was positive for its primary end point (10.6 months in the regorafenib group vs 7.8 months, HR: 0.63). Moreover, regorafenib significantly prolonged time to disease progression (3.1 vs 1.5 months). The efficacy of the substance was consistent in all relevant subgroups. Sequential administration of sorafenib and regorafenib resulted in an OS of 26 months compared with 19 months in patients receiving only sorafenib as first-line and placebo as second-line treatment \[[@B49]\]. Cabozantinib is another TKI targeting VEGFR1-3, MET and AXL \[[@B50]\]. The CELESTIAL study compared the efficacy of cabozantinib in patients after failure of a sorafenib-based first-line therapy against placebo \[[@B48]\]. Cabozantinib led to a significant improvement in OS (10.2 months in the cabozantinib arm vs 8.0 months in the placebo arm) with acceptable toxicity. Other oncological end points (PFS; ORR) were also positively influenced. As already pointed out, the combination of cabozantinib and checkpoint inhibitors was recently tested within the cabozantinib cohort (cohort 6) of the CheckMate-040 trial. This arm featured both sorafenib-naive and sorafenib-experienced patients. A separate evaluation for these two groups is not yet available; nevertheless, the combination was associated with numerically high ORR, PFS and OS rates (see above \[[@B34]\]).

Since RESORCE and CELESTIAL did not include an active comparative arm, it is unclear whether one substance is superior or inferior to the other. Biomarkers that enable the selection of patients for one of the substances have not yet been identified. In this context, analyses of blood samples from the RESORCE study recently identified a total of five proteins (angiopoietin 1, cystatin B, the latency-associated peptide of TGF-β1, oxidized low-density lipoprotein receptor 1 and C-C motif chemokine ligand 3) that were associated with prolonged survival upon treatment with regorafenib \[[@B51]\]. In addition, nine plasma miRNA (MIR30A, MIR122, MIR125B, MIR200A, MIR374B, MIR15B, MIR107, MIR320 and MIR645) were correlated with an improved survival. To what extent these findings will become clinically relevant remains to be seen.

Ramucirumab {#S0009}
-----------

In 2015, the REACH study demonstrated that, after the failure of sorafenib, HCC patients with high AFP serum concentrations (\>400 ng/ml) may benefit from therapy with the VEGFR2 antibody ramucirumab (7.8 months for ramucirumab vs 4.2 months for placebo; p = 0.006; \[[@B52]\]). This retrospective analysis led to the REACH-2 study, which investigated the efficacy of ramucirumab in the second-line treatment of HCC specifically in patients with baseline AFP \>400 ng/ml in a randomized Phase III design \[[@B52]\]. In this study, patients with advanced HCC and baseline AFP \>400 ng/ml who were progressive under first-line sorafenib therapy were randomized to an arm receiving the VEGFR2 antibody ramucirumab or placebo. The administration of ramucirumab resulted in a small but significant improvement in survival (8.5 months in the ramucirumab arm vs 7.3 months in the placebo arm) with an acceptable toxicity profile. Importantly, the study confirms the feasibility of biomarker-guided therapies in HCC.

Immunotherapy {#S0010}
-------------

After the failure of sorafenib, both pembrolizumab (an anti-PD-1 monoclonal antibody) and nivolumab (a fully humanized monoclonal antibody against PD-1) demonstrated efficacy in Phase Ib studies (CheckMate-040 \[[@B7]\] and Keynote-224 \[[@B8]\]). However, for pembrolizumab, these results could not be confirmed in the Phase III, randomized double-blind keynote-240 trial, which included a total of 413 patients with pretreated advanced HCC (31790344) at 119 medical centers in 27 countries. The patients received either pembrolizumab or placebo. The median OS was 13.9 months in the pembrolizumab arm versus 10.6 months in the placebo arm (HR: 0.781; p = 0.0238), the median PFS was 3.0 versus 2.8 months (HR: 0.718; p = 0.0022). However, since the prespecified alpha level was significantly lower, the study must be considered statistically negative. Similar to PD-L1 antibodies, CTLA-4 antibodies were also tested in second-line therapy of HCC; Sangro *et al.* described promising results (response rate was 17.6% and a median time to progression was 6.48 months) from 21 patients treated with tremelimumab at a dose of 15 mg/kg intravenously every 90 days \[[@B53]\]. Based on the promising results of the CheckMate-040 trial, which reported an ORR of 14% and median OS of 16 months, the efficacy and safety of the combination of nivolumab and ipilimumab was tested in sorafenib treated patients with advanced HCC \[[@B34]\]. One hundred and forty eight patients were randomized into three arms: nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks (Q3W) (four doses) or nivolumab 3 mg/kg + ipilimumab 1 mg/kg Q3W (four doses), each followed by n 240 mg Q2W, or nivolumab 3 mg/kg Q2W + ipilimumab 1 mg/kg Q6W. Overall, ORR was 31% (with a median duration of response of 17 months), disease control rate was 49% and 24-month survival rate was 40%. Of note, the first arm demonstrated the most promising efficacy (OS: 23 months). Interestingly, the different combinations were well tolerated, potentially offering a novel treatment option for patients with pretreated HCC. The combination of nivolumab, ipilimumab and cabozantinib \[[@B34]\] is reported above.

Conclusion {#S0011}
==========

After a decade of negative trials, various new drugs have entered the field and in some cases demonstrated superior efficacy compared with sorafenib when used as first-line treatments for patients with HCC. From the IMBRAVE-150 study, it can be expected that the combination of atezolizumab plus bevacizumab will represent the new standard for untreated patients in the near future, optimal treatment sequences are only poorly investigated and remain to be defined ([Figure 1](#F1){ref-type="fig"}). Moreover, currently, besides AFP, no biomarker is available for the identification of patients that will benefit from a certain treatment. Current data highlights that specific subgroups of patients (such as patients with nonviral etiology of liver cirrhosis) might benefit to a much lesser extend from the current advances and represent a group with a high need for novel treatments. Thus, the introduction of novel combination therapies into therapy of patients with HCC does not represent the 'end of history' but only a novel chapter on the way to an optimal treatment of all patients with primary liver cancer.

![Proposed treatment algorithm of medical treatment in hepatocellular carcinoma patients.](hep-07-20-g1){#F1}

Future perspective {#S0012}
==================

Recent results from large Phase III trials have somewhat overshadowed results from Phase II trials analyzing molecular guided strategies in patients with HCC. Based on data from molecular analysis on HCC samples (e.g., \[[@B54]\]) current studies, addressing TGF-β1-, MET-, BRAF- and FGFR4-pathways, have generated promising results with well-tolerated active agents suitable for future combinations \[[@B10]\]. Such trials might open the door for personalized approaches in HCC in order to provide each individual patient with an optimal treatment. Innovative trial designs, similar to other areas of oncology, are warranted to allow the early testing of drug combinations as well as defining the optimal sequence of single and combined agents.
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